Creation and Validation of cell-based screening systems for SARS-CoV-2 drug targets
SARS-CoV-2 药物靶标细胞筛选系统的创建和验证
基本信息
- 批准号:10618835
- 负责人:
- 金额:$ 19.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-06 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAmino AcidsAntiviral AgentsAppearanceBiological AssayBiosensorCOVID-19 vaccineCell LineCellsChymaseCodeComplexCoronavirusDevelopmentDisease OutbreaksDoseDrug ScreeningDrug TargetingEconomicsEnzyme InhibitionEnzyme Inhibitor DrugsEnzymesExhibitsFDA approvedFirefly LuciferasesFluorescenceFutureGenomic DNAHealthHumanHydroxychloroquineIndividualInfectionLibrariesLuciferasesLungMessenger RNANational Center for Advancing Translational SciencesPeptide HydrolasesPharmaceutical PreparationsPlasmidsPoint MutationPolyproteinsProteinsRNA Polymerase InhibitorRNA-Directed RNA PolymeraseRecoveryRenilla LuciferasesResearch PersonnelRibonucleic Acid Regulatory SequencesSARS-CoV-2 antiviralSARS-CoV-2 infectionSARS-CoV-2 inhibitorSeriesSiteSystemTestingTherapeuticTransfectionTranslatingUncertaintyUnited States National Institutes of HealthVaccinesValidationViralViral GenomeViral PhysiologyViral ProteinsVirus Diseasesantiviral drug developmentcoronavirus antiviralcoronavirus pandemicdesignenzyme activityexpression vectorimprovedin vitro activityinhibitornovel coronavirusred fluorescent proteinresistant strainresponsescreeningscreening programstable cell linevaccine acceptancevectorzoonotic coronavirus
项目摘要
Project Summary/Abstract:
Effective antivirals are sorely needed against SARS CoV-2 (CoV2), and coronaviruses (CoV) in
general. Screening systems for drugs targeting CoV2 enzymes usually involve screening against
purified enzymes. This can be technically challenging, and the vast majority of inhibitors identified
ultimately lack utility as antivirals because: they may not be transported into and retained in cells,
altered within cells such that they no longer inhibit the target effectively, or exhibit off-target effects that
preclude their use as therapeutics. Using predicted drugs directly in viral infection assays can exhibit
off-target effects against the host cell or other viral proteins and can be difficult to distinguish within the
context of the viral infection (the inhibition of CoV2 infection by hydroxychloroquine is one such
example). Ideally screens for viral enzymes isolate the enzyme from the viral infection, but evaluate
function within human cells. We have constructed vectors for expression of four wild-type CoV2
proteins, and unique biosensors, to evaluate function of two CoV2 enzymatic functions, the CoV Main
Protease and the CoV RNA-dependent RNA polymerase complex. We are completing assay validation
and beginning to use the assays to evaluate the few known inhibitors of these enzymes. The protease
assay will be converted to a stable cell line for large scale screening programs. The transfection assays
will be evaluated using both established and experimental 3CL and RdRpC inhibitors, and 128 FDA-
approved drugs that we have predicted target these enzymes, to validate the usefulness of these
screening assays. Drugs that show inhibition of activity will be quantified using dose-response analysis
in the cell-based assays, and subsequently analyzed for inhibition of CoV2 infection of cultured human
lung cells across a similar dose-response range. Following validation, vectors and/or stable cells lines
for the cell-based drug screening systems will be made readily available to other researchers, such as
NIH’s NCATS, who are currently seeking CoV antiviral agents.
项目摘要/摘要:
迫切需要有效的抗病毒药物来对抗 SARS CoV-2 (CoV2) 和冠状病毒 (CoV)
一般的。针对 CoV2 酶的药物筛选系统通常涉及筛选
纯化的酶。这在技术上具有挑战性,并且绝大多数抑制剂已被识别
最终缺乏作为抗病毒药物的效用,因为:它们可能不会被转运到细胞中并保留在细胞中,
细胞内发生改变,使其不再有效抑制靶标,或表现出脱靶效应
阻止它们用作治疗药物。直接在病毒感染测定中使用预测药物可以表现出
针对宿主细胞或其他病毒蛋白的脱靶效应,并且很难在
病毒感染的背景(羟氯喹抑制 CoV2 感染就是其中之一)
例子)。理想的情况是筛选病毒酶,将酶从病毒感染中分离出来,但评估
在人体细胞内发挥作用。我们构建了表达四种野生型 CoV2 的载体
蛋白质和独特的生物传感器,以评估两种 CoV2 酶功能的功能,即 CoV Main
蛋白酶和 CoV RNA 依赖性 RNA 聚合酶复合物。我们正在完成分析验证
并开始使用测定法来评估这些酶的少数已知抑制剂。蛋白酶
检测将转化为稳定的细胞系,用于大规模筛选计划。转染测定
将使用已建立的和实验性的 3CL 和 RdRpC 抑制剂以及 128 种 FDA-
我们预测以这些酶为目标的批准药物,以验证这些酶的有用性
筛选分析。将使用剂量反应分析对表现出活性抑制作用的药物进行定量
在基于细胞的检测中,随后分析了对培养人类的 CoV2 感染的抑制作用
肺细胞具有相似的剂量反应范围。验证后,载体和/或稳定细胞系
基于细胞的药物筛选系统将易于其他研究人员使用,例如
NIH 的 NCATS 目前正在寻找 CoV 抗病毒药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS MELENDY其他文献
THOMAS MELENDY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS MELENDY', 18)}}的其他基金
Creation and Validation of cell-based screening systems for SARS-CoV-2 drug targets
SARS-CoV-2 药物靶标细胞筛选系统的创建和验证
- 批准号:
10373681 - 财政年份:2022
- 资助金额:
$ 19.94万 - 项目类别:
Slowing of the polyomavirus DNA replication fork in response to DDR
DDR 导致多瘤病毒 DNA 复制叉减慢
- 批准号:
10408848 - 财政年份:2021
- 资助金额:
$ 19.94万 - 项目类别:
Slowing of the polyomavirus DNA replication fork in response to DDR
DDR 导致多瘤病毒 DNA 复制叉减慢
- 批准号:
10289169 - 财政年份:2021
- 资助金额:
$ 19.94万 - 项目类别:
Evaluation and development of E1-TopoI as a target for anti-HPV therapeutics
E1-TopoI 作为抗 HPV 治疗靶点的评估和开发
- 批准号:
8297142 - 财政年份:2012
- 资助金额:
$ 19.94万 - 项目类别:
Evaluation and development of E1-TopoI as a target for anti-HPV therapeutics
E1-TopoI 作为抗 HPV 治疗靶点的评估和开发
- 批准号:
8450078 - 财政年份:2012
- 资助金额:
$ 19.94万 - 项目类别:
Evaluation and development of E1-TopoI as a target for anti-HPV therapeutics
E1-TopoI 作为抗 HPV 治疗靶点的评估和开发
- 批准号:
8638888 - 财政年份:2012
- 资助金额:
$ 19.94万 - 项目类别:
MECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTS
DNA 损伤触发 S 相检查点的机制
- 批准号:
6833488 - 财政年份:2001
- 资助金额:
$ 19.94万 - 项目类别:
MECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTS
DNA 损伤触发 S 相检查点的机制
- 批准号:
6626784 - 财政年份:2001
- 资助金额:
$ 19.94万 - 项目类别:
MECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTS
DNA 损伤触发 S 相检查点的机制
- 批准号:
6229425 - 财政年份:2001
- 资助金额:
$ 19.94万 - 项目类别:
MECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTS
DNA 损伤触发 S 相检查点的机制
- 批准号:
6692971 - 财政年份:2001
- 资助金额:
$ 19.94万 - 项目类别:
相似海外基金
Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
- 批准号:
BB/Y006380/1 - 财政年份:2024
- 资助金额:
$ 19.94万 - 项目类别:
Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
- 批准号:
24K17112 - 财政年份:2024
- 资助金额:
$ 19.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
- 批准号:
23K04668 - 财政年份:2023
- 资助金额:
$ 19.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
- 批准号:
23K06918 - 财政年份:2023
- 资助金额:
$ 19.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
- 批准号:
23K05758 - 财政年份:2023
- 资助金额:
$ 19.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Design and Synthesis of Fluorescent Amino Acids: Novel Tools for Biological Imaging
荧光氨基酸的设计与合成:生物成像的新工具
- 批准号:
2888395 - 财政年份:2023
- 资助金额:
$ 19.94万 - 项目类别:
Studentship
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
- 批准号:
2300890 - 财政年份:2023
- 资助金额:
$ 19.94万 - 项目类别:
Continuing Grant
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
- 批准号:
10761044 - 财政年份:2023
- 资助金额:
$ 19.94万 - 项目类别:
Lifestyle, branched-chain amino acids, and cardiovascular risk factors: a randomized trial
生活方式、支链氨基酸和心血管危险因素:一项随机试验
- 批准号:
10728925 - 财政年份:2023
- 资助金额:
$ 19.94万 - 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
- 批准号:
10757309 - 财政年份:2023
- 资助金额:
$ 19.94万 - 项目类别:














{{item.name}}会员




